Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4.24 (market cap $2.14B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.78 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 78.7× Recursion Pharmaceuticals Inc's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard Emerging Markets Stock Index Fund ETF for 134 Days on average.
| RXRX | VWO | |
|---|---|---|
Market Cap | $2.14B | $168.50B |
Volume | 30,789,535 | 9,650,999 |
Sector | Health | — |
52-Week High | $6.79 | $61.44 |
52-Week Low | $2.84 | $52.42 |
Typical Hold Time | 22 Days | 134 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
VWO trades at $59.85, down 1.27% with a bearish technical signal. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic weakness creates headwinds. Institutional ownership has increased with Allianz Asset Management growing its stake by 12.6% in Q3 2026, though technical indicators show selling pressure outweighing buying signals.
The outlook remains cautious with emerging markets facing economic divergence. Opportunities exist in semiconductor and technology exposure, but risks include China's property slump and currency volatility. Wall Street sentiment is neutral with the ETF trading near key support levels amid global market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
